Rebuilding Reputations: COVID-19 Presents A Big Responsibility And Opportunity
Executive Summary
The global COVID-19 crisis has presented a chance for industry to improve its reputation by highlighting the value of its R&D engines. Pharma executives and observers outline why they are optimistic about a chance to regain public trust.
You may also be interested in...
Trump’s Executive Order Limiting Medicare Drug Payments Faces Hurdles
Under test payment model, Medicare would pay no more than most-favored-nation price for Part B and Part D drugs, but how and when the model program would be implemented remains unclear. BIO may pursue legal action as questions on how plan would be implemented and if the administration will provide notice and comment period for stakeholder input remain.
A Biopharma A-List Lineup Aims To Tackle Complex Manufacturing At Resilience
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.
Regeneron Leaders On Getting A Call From Trump And Building A Bioreactor Farm
Regeneron CEO Len Schleifer and President George Yancopoulos talked at the Stat Summit about launching their COVID-19 antibody cocktail and planning for the next pandemic.
Need a specific report? 1000+ reports available
Buy Reports